PM Society and CIM launch new leadership programme for pharma marketers
Ella Day | June 13, 2025 | News story | Sales and Marketing | CIM Fellowship, Chartered Institute of Marketing (CIM), Corporate, Marketing Excellence Industry Group, PM Society Awards, Pharmaceutical Marketing (PM) Society, Pharmacy, partnership
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to launch the PMS & CIM Marketing Leaders Programme – a new initiative aimed at strengthening strategic capability and standards within pharma marketing.
The programme will consist of a series of three-day, in-person training sessions delivered by senior CIM course directors at the institute’s headquarters in Berkshire, UK, this October. Workshops will focus on strategic marketing and personal branding, with an emphasis on leadership development.
Ten senior pharma marketing or brand managers will be selected to participate. Following completion, three outstanding candidates will be awarded CIM Fellowships, presented on stage at the PM Society Awards in March, 2026.
Funded by the PM Society, the initiative forms part of its Marketing Excellence Industry Group, co-chaired by Simon Grime and Ed Thesiger. Applications are open to professionals who meet CIM’s criteria and are seeking to advance into more senior roles.
“This is a very exciting partnership,” said Grime, partner at the PM Society. “It aims to promote progress for those who have been in the industry for several years and are ready to broaden their remit.”
Chris Daly, CEO of the CIM, added: “This programme will further embed the value of developing high-level capability and performance.”
Ella Day
13/6/25
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases
Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development …
